Abstract: The invention can be used in biotechnology, in particular to the gene therapy DNA vector GDTT1.8NAS12, Escherichia coli strain JM 110-NAS, Escherichia coli strain JM 110-NAS/GDTT1.8NAS12, and the industrial production of the gene therapy DNA vector GDTT1.8NAS12. A method of obtaining the gene therapeutic DNA vector GDTT1.8NAS12 involves construction of a 2408-bp intermediate vector containing a 688-bp replication origin, a 467-bp transcription terminator hGH-TA, a 137-bp regulatory site RNA-out transposon TnIO, a I0I8-bp kanamycin resistance gene, and a 68-bp polylinker. Then, it is splitted using restriction endonucleases SalI and BamHI and ligated to the promoter regulatory region containing the 1219-bp promoter region of the human elongation factor EF1A with its own enhancer. The kanamycin resistance gene is cleaved at the SpeI restriction sites.